TekniPlex Rebrands, Streamlining Corporate Identity

All legacy business unit brands transitioning to uniformly aligned corporate image, further strengthening TekniPlex’s presence in various sectors

TekniPlex, a leading materials science solutions partner, has announced a comprehensive rebrand intended to streamline its corporate identity and further leverage its broad name recognition.

The global effort comes as TekniPlex is in the midst of unprecedented growth. With 15 acquisitions in the last five years, the company has effectively doubled in size. This growth culminated in a recent reorganization of its lines of business into two primary divisions: TekniPlex Healthcare and TekniPlex Consumer Products. The rebrand is the next market-facing step in this evolution.

“By consolidating all brands under the TekniPlex name, we will be able to better service our customers by providing them greater visibility into the full-breadth of our capabilities and offerings,” said Brenda Chamulak, President & CEO of TekniPlex. “We will also be able to more thoroughly leverage the synergies between our businesses, and solidify our position as a leading materials science solutions partner to many of the world’s largest brands.”

The updated brand structure unites all business units under two divisions — Healthcare and Consumer Products. Previous business unit brand names will no longer be used in market-facing environments. The transition to a more uniform market presence will take place over time.

Uniting under the TekniPlex Healthcare division brand are legacy business units Colorite, Natvar, Dunn, JPG, TekniPlex Flexibles, TekniFilms, TekniPlex Europe, TekniPlex Gallazzi, Beyers Plastics, Lameplast and LF of America, previously known as “Medical” and “Healthcare Packaging”.

Uniting under the TekniPlex Consumer Products division are legacy businesses Dolco, TriSeal, Action Technology, MMC Packaging Equipment, Grupo Phoenix, M-Industries, Geraldiscos, Keyes and Fibro.

SourceTekniPlex

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version